Objective:To research the stability and degradation kinetics of NVB solution and its liposome. Methods:The light and thermal stabilities of NVB solution and its liposome were studied and the degradation kinetics was also investigat ed,the model was fit. Results:Both the light degradation kinetics of NVB solution and its liposome fit the zero-order kinetics; the thermal degradation of solution group at 40℃ fit the first-order kinetics,and the liposome group fit the zero-order kinetics; both the solution and liposome group at 60℃ fit the first-order kinetics. Conclusion:The liposome can significantly improve the light and thermal stabilities of NVB.

Objective To develop a RP-HPLC method for the determination of curcumin in rats plasma.Method After the plasma was treated,the samples were separated well on a DiamonsilC18 column(4.6 mm × 250 mm,5 μm) under room temperature;the mobile phase was acetonitrile:2% acetic acid solution(58∶42) at a flow rate of 1.0 ml/min;the detective wavelength was 426 nm.Results Curcumin could be successfully separated from internal standard substance and other endogenous interference components under the chromatographic conditions.Liquid-liquid extraction method adopted to treat the plasma samples had the highest recovery rate.Between 0.1 and 0.5 mg/L,the method had a good linear relationship,while the regression equation was y=0.0026x-0.0756,r=0.9984;the within-day and between-days precision RSD were less than 10%;the average method recovery and the average extraction recovery were more than 90%.Conclusion The RP-HPLC method for the determination of curcumin in rat plasma is accurate and reliable,which could be applied to determine the curcumin concentration in the blood.

目的观察来氟米特诱导和维持治疗Ⅳ型及Ⅴ型狼疮肾炎(LN)的疗效及安全性。方法单中心前瞻性临床研究。选取1个月内经病理证实的Ⅳ犁及Ⅴ型狼疮肾炎患者,在使用激素的基础上随机入组分别使用来氟米特(口服30 mg/d,LEF组)或环磷酰胺(静1 g/月, CTX组)。6个月后,维持方案为LEF组续用LEF 20 mg/d,CTX组续用CTX 1 g/3月,两组泼尼松均使用5～10 mg/d。评价治疗的安全性和有效性:结果共40例患者进入试验,其中LEF组19例,CTX组21例;LEF组17例、CTX组18例完成了诱导期治疗。LEF组诱导治疗总有效率达88.2%,完全缓解率为52.9%;CXT组治疗总有效率为72.2%,完全缓解率为44.4%;两组间差异无统计学意义。缓解的患者中,LEF组有7例进入维持期治疗,随访时间(18.6±6.5)月,未出现蛋白尿复发,其中3例进行了重复肾活检,结果显示肾脏病理类型均由重转轻,活动性指数下降,但慢性指数有所上升。CTX组有11例进入维持期治疗,随访时间(25.1±9.6)月,其中有3例在随访中蛋白尿复发。LEF组发生不良反应14例次,主要是感染,以带状疱疹多见。环磷酰胺组发生不良反应18例次,主要为感染和月经不调,组间比较差异无统计学意义。结论来氟米特联合激素诱导及维持治疗Ⅳ犁及Ⅴ型LN疗效显著,患者耐受性良好。

AIM: To evaluate the efficacy and safety of lomefloxacin injection in the treatment of acute bacterial infections. METHODS: A total of 190 patients (160 patients in a randomized trial, 30 patients in an open trial) were divided into 2 groups. One hundred and ten patients (M 54,F 56; age 54 a± s 11 a) in treatment group received 200-400 mg,iv,qd for 7-10 d. Eighty patients (M 45,F 35; age 53 a±10 a) in control group received ciprofloxacin 200-400 mg,iv,bid, for 7-10 d. RESULTS: The effective rate and the bacterial clearance rate of the treatment group were 86% and 81% respectively, and that of the control group were 80% and 73% respectively. No significant difference was found between the 2 groups ( P 0.05). The adverse reaction of lomefloxacin was 4%. CONCLUSION: Lomefloxacin is the effective and safe antibacterial in the treatment of bacterial infections.